By applying a diversity oriented synthesis strategy for the search of new antagonists of the thrombin receptor PAR1, a series of peptide-based ureas and thioureas, including analogues of the PAR1 reference antagonist RWJ-58259, has been designed and synthesized. The general synthetic scheme involves reduction of basic amino acid-derived amino nitriles by hydrogen transfer from hydrazine monohydrate in the presence of Raney Ni, followed by reaction with diverse isocyanates and isothiocyanates, and protecting group removal. All new compounds have been evaluated as inhibitors of human platelet aggregation induced by the PAR1 agonist SFLLRN. Some protected peptide-based ureas displayed significant antagonist activity.
Introduction
In addition to the key role of thrombin in the blood coagulation cascade [1] , this serine protease regulates multiple effects on an increasing variety of cells, such as: platelets [2, 3] , endothelial and smooth muscle cells [2, 4] , neurons and astrocytes in the nervous system [2, [4] [5] [6] [7] , immune and inflammatory cells [8, 9] , osteoblasts [10] , and tumor cells [11] [12] [13] [14] . These cellular effects are mainly mediated by the activation of the protease-activated receptor PAR1 [15] . This is a G-protein coupled receptor (GPCR) that is activated by the thrombin-catalyzed cleavage of the N-terminal extracellular domain at the Arg 41 /Ser 42 peptide bond, which unveils the recognition sequence SFLLRN that acts as a tethered activation ligand. The conformational changes induced by activation favors the coupling of PAR1 with heterotrimeric G-proteins, which consequently activate complex cellular signaling cascades [16, 17] .
Since PAR1 is mainly expressed in platelets, where its activation induces aggregation, it has been proposed that PAR1 antagonists could be good antithrombotic agents without the hemorrhagic drawbacks of thrombin inhibitors. Based on this suggestion, up to now, PAR1
antagonists have been searched almost exclusively in relation to the cardiovascular system [3, 18, 19] . However, numerous studies have shown that PAR1 is overexpressed in invasive and metastatic tumors and that its expression levels directly correlate with the degree of invasiveness of the cancer [20] [21] [22] [23] [24] [25] [26] [27] [28] . Based on these facts, this receptor is starting to be also considered a promising target for cancer therapy [15] , particularly in the search of angiogenesis inhibitors [29] .
The first potent PAR1 antagonists were SFLLRN-based peptidomimetic ureas, represented by the optimized antagonist RWJ-58259 ( Figure 1 ) [19] . This antagonist showed protection against thrombus formation in nonhuman primates, providing the first in vivo proof for supporting the potential clinical utility of PAR1 antagonists, although, its low oral bioavailability stopped its clinical development [19] . Later, several laboratories have reported a few series of antagonists obtained from HTS of diverse libraries of non-peptide small molecules, followed by optimization [19, 30] . The most advanced of these antagonists is SCH-530348 (named vorapaxar, Figure 1 ), derived from the natural product himbacine, which currently is undergoing Phase III clinical trials in patients with acute coronary syndrome and in patients with atherosclerosis [31] [32] [33] . Up to now, there is not structural information on the binding sites of these PAR1 antagonists to be used for structure-based design of new antagonists. However, recent mutagenesis studies on thrombin and/or PAR1 [34] [35] [36] [37] [38] [39] [40] [41] [42] , X-ray of thrombin crystallized with diverse N-terminal fragments of PAR1 [43, 44] , and NMR studies on the (Ala 26 -Hse 103 ) N-terminal sequence of PAR1 [45] have shown that the first thrombin/PAR1 interaction is produced between the exosite I of thrombin and the hirudin-like sequence of PAR1 (K 51 YEPF 55 ), and that this first interaction is essential and determinant for high affinity. It seems that the hydrophobic residues F34, I82, L65 and Y76, and the basic residues R67 and R73, of the exosite I of thrombin are important for high affinity. Taking into account this knowledge, we started a project directed to the search of new PAR1 antagonists based on these hot spots of the exosite I of thrombin for PAR1. As these hot spots are discontinuous and are not localized in a defined secondary structure, we decided to use a diversity oriented synthesis (DOS) strategy for the search of peptidomimetics. For this purpose, we planned the synthesis of diverse small directed libraries of different scaffolds able to display, at least, one or two aromatic groups and one or two basic groups at variable distances and orientations. Among these structures, our first objective was the synthesis of ureas and thioureas of general formula A, which could be considered as analogues of the reference antagonist RWJ-58259. To this aim, we devised a synthetic scheme using basic amino acid derived α-amino nitriles 1 and 2 ( Figure 1 ) as key diversity generation intermediates [46] . Herein, we report the synthesis of ureas and thioureas A and their evaluation as human PAR1 antagonists in a platelet aggregation assay.
Results and discussion

Synthesis
The proposed general synthetic scheme for the preparation of ureas and thioureas A involves cyano-reduction of the protected α-amino nitriles 1 and 2, followed by reaction of the resulting primary amines with isocyanates or isothiocyanates and subsequent removal of protecting groups. The starting basic amino acid-derived α-amino nitriles 1 and 2 were obtained by a modified Strecker reaction as (1:1) epimeric mixtures at the cyano-supporting stereocenter, except for the arginine derivatives 1c, which were obtained in an (R)/(S) ratio of The epimeric mixture (RS)-1a was used as a model for optimizing the cyano reduction.
Initially, this was attempted by 10% Pd(C) or Raney Ni catalyzed hydrogenation. However, as shown in Scheme 1 and Table 1 , the HPLC MS analysis of the crude reaction showed that the expected primary amines (RS)-3a were obtained along with variable percentages of 5a and 6a, resulting from retro-Strecker reaction and reduction of the intermediate imine after
removal of HCN, respectively. The difficulties in the purification of (RS)-3a from the crude reaction mixtures moved us to try the reduction by hydrogen transfer, using hydrazine monohydrate as hydrogen source and Raney Ni as catalyst [48] . After the study of reaction conditions (Table 1) , the formation of the side product 6a could be completely avoided, but not that of the retro-Strecker reaction 5a. This side reaction was minimized to a 5 % by carrying out the reduction under refluxing MeOH for 5 min, using 20 equivalents of hydrazine monohydrate and 100 mg/mmol of Raney Ni (entry 7). These optimized conditions were applied to the reduction of the other starting α-amino nitriles. It is interesting to point out the importance of the Raney Ni activation, as well as the efficiency of the stirring, to make the reduction as faster as possible, in order to minimize the presence of the amino nitrile within the reaction medium, for minimizing the retro-Strecker reaction. Besides, in the phenylacetaldehyde derivatives 3 (m =1), the reduction of the (R)-epimer was slower than that of the corresponding (S)-epimer and, consequently, its percentage of degradation via retroStrecker was significantly higher [see for example different yields for reduction of (R)-and (S) epimers of 1a and 1b in Table 2 ]. In the case of the Arg derivative 3c, the difference in reactivity between epimers made that the minor (R)-epimer were lost in the reduction. Due to the difficulties found in the separation of the primary amines 3 and 4 from the side product of the retro-Strecker reaction 5, the crude reduction mixtures were initially used without purification for the synthesis of the desired ureas 8 and 9. However, the difficulties in the purification of these ureas remained, and several column chromatographies were required for their separation from the ureas 10, byproducts derived from the amino amides 5, with considerable loss in the yield. Only the epimeric mixture of ornithine-derived ureas (RS)-9a
could be resolved during this chromatographic purification. The Fmoc-removal in 12a-c, followed by reaction with different aromatic isocyanates (Scheme 2) led to the desired ureas 8 and 13-16 in significantly higher overall yields than by the direct synthesis of the urea after the cyano-reduction (compare yields of methods A and B in Table 2 ).
Table 2
Optimization of the synthesis of ureas 8, 9 and 13-17 c Overall yield of reduction, followed by reaction with the corresponding isocyanate (Method A).
Amino nitrile Diamine
d Overall yield of reduction, followed by sequential Fmoc-protection, isolation, Fmoc-deprotection, and reaction with the corresponding isocyanate (Method B). and the low overall yield of the arginine-derived urea 8c, this urea was not deprotected.
The lysine-derived Fmoc protected diamine 12b was also used for the synthesis of the PAR1 reference antagonist RWJ-58259 analogue (S)-25b (Scheme 3). This urea was synthesized by applying our recently reported procedure for the preparation of RWJ-58259 [50] . This procedure involves the in situ formation of the indazole-derived isocyanate 23, by reaction of the required 6-amino-indazole 22 with triphosgene in the presence of propylene oxide as HCl acceptor, followed by reaction with the deprotected diamines (R)-and (S)-3b.
Interestingly, as commented for the reduction of the starting amino nitriles, the application of 
Biological evaluation
Since PAR1 is mainly expressed in platelets, to evaluate the PAR1 antagonist activity, all new compounds were screened as inhibitors of human platelet aggregation induced by a 30 µM concentration of the PAR1 agonist SFLLRN. The antagonist RWJ-58259 was used as a reference. At a 10 M concentration this antagonist inhibited 98% the platelet aggregation.
All compounds were tested at an initial concentration of 0.1 mg/mL (≈ 150 M).
Unfortunately, none of the deprotected ureas or thioureas inhibited the platelet aggregation.
However, as shown in Figure 2 , some of the protected ureas, and particularly the Fmoc intermediates 12, showed significant inhibition. Thus, the Fmoc derivatives (S)-12a and (S)-12c inhibited a 51 % and a 36 %, respectively, the platelet aggregation. Among the protected ureas and thioureas, the most potent were the urea (R)-8b and the thiourea (S)-26a, which showed 38 and 33 % of inhibition, respectively. Although these results do not allow to establish defined structure-activity relationships, it seems that in the Fmoc derivatives 12 and thioureas 26a, the (S)-epimers showed higher inhibition % than the respective (R). However, In the structural comparison of the inactive indazole-derived urea (S)-25b with the family of peptidomimetic urea PAR1 antagonists, to which the reference antagonist RWJ-58259
belongs [51] , the main difference is the replacement of the di(F)-Phe residue of RWJ-58259
by the 1-amino-3-phenyl-propan-2-yl moiety in (S)-25b (see Figure 1 ). This replacement involves the loss of the carbonyl group of the peptide bond, which could be important for the interaction with the PAR1 receptor, participating in H-bond formation or for the appropriate orientation of the pharmacophoric groups. These results could be a good clue for the search of new potent PAR1 antagonists and to explore the thrombin/PAR1 interaction.
Experimental
General
All reagents were of commercial quality. The NMR spectra assignment was based on COSY, HSQC, and HMBC spectra.
General procedure for the synthesis of basic amino acid-derived ureas. Method A.
Synthesis of ureas (RS)-8a,b and -9a,b, and (R)-and (S)-9a
Raney Ni (30 mg) and hydrazine monohydrate (0.186 mL, 6 mmol) were added to a 
4.2.1.
N  -Boc-N  -[(2R)-4-Phenyl-1-(3-phenylureido)butan-2-yl]-ornithine benzyl amide [(R)-9a]
N
 -Boc-N  -[(2S)-4-Phenyl-1-(3-phenylureido)butan-2-yl]-ornithine benzyl amide [(S)-9a]4.3.1. N  -Boc-N  -[(2R)-3-Phenyl-1-(Fmoc)amino-propan-2-yl)-ornithine benzyl amide [(R)-
 -Boc-N  -[(2S)-3-Phenyl-1-(Fmoc)amino-propan-2-yl)-ornithine benzyl amide [(S)- 12a]4.3.3. N ε -Boc-N  -[(2R)-3-Phenyl-1-(Fmoc)amino-propan-2-yl)-lysine benzyl amide [(R)- 12b]4.3.4. N ε -Boc-N  -[(2S)-3-Phenyl-1-(Fmoc)amino-propan-2-yl)-lysine benzyl amide [(S)- 12b]4.3.5. N  -Pbf-N  -[(2S)-3-Phenyl-1-(Fmoc)amino-propan-2-yl)-arginine benzyl amide [(S)- 12c]
General procedure for the synthesis of basic amino acid-derived ureas. Method B.
Synthesis of ureas (R)-8a,b, (S)-8a-c, (R)-and (S)-13a, and (R)-and (S)-14-16b
Diethyl amine (0.32 mL, 3 mmol) was added to a solution of the corresponding Fmocprotected amine 12a-c (0.3 mmol) and the reaction mixture was stirred at rt for 2 h. Then, the solvent was evaporated to dryness and the residue was dissolved in EtOAc (50 mL). The solution was successively washed with H 2 O (20 mL) and brine (20 mL), dried over Na 2 SO 4 , and evaporated to dryness. The residue was dissolved in dry CH 2 Cl 2 (10 mL), cooled at 0ºC.
The corresponding isocyanate (0,3 mmol) was added to this solution and the mixture was 
N
 -Boc-N  -[(2S)-3-Phenyl-1-(3-phenylureido)propan-2-yl]-ornithine benzyl amide [(S)-8a]4.4.3. N ε -Boc-N  -[(2R)-3-Phenyl-1-(3-phenylureido)propan-2-yl]-lysine benzyl amide [(R)- 8b]
4.4.12.
N ε -Boc-N  -[(2R)-1-(3-(4-Fluorophenethyl)ureido)-3-phenyl)propan-2-yl]-lysine benzyl amide [(R)-16b]
General procedure for the N-Boc-deprotection of protected ureas (RS)-9b, (R)-and (S)-8a,b, (R)-, (S)-9a and -13a, (R)-and (S)-14-16b. Synthesis of urea hydrochlorides (R)-and (S)-11a, (RS)-11b, (R)-and (S)-17a,b, (R)-and (S)-18a, (R)-and (S)-19-21b
The corresponding protected urea (0.10 mmol) was dissolved in a 3M solution of HCl in EtOAc (2 mL) and stirred at rt for 2 h. Then, the solvent was evaporated under reduced pressure, the residue was dissolved in H 2 O (3 mL) and the solution was lyophilized. 
N-Boc deprotection of (S)-24b. Synthesis of
The protected urea (S)-24b (130 mg, 0.15 mmol) was dissolved in a 3M solution of HCl in EtOAc (2 mL) and stirred at rt for 2 h. Then, the solvent was evaporated under reduced pressure, the residue was dissolved in H 2 O (3 mL) and the solution was lyophilized to give the urea (S)-25b (131 mg, 100% 
General procedure for the synthesis of thioureas (R)-and (S)-26a
Diethyl amine (0.32 mL, 3 mmol) was added to a solution of the corresponding Fmocprotected amine (R)-and (S)-12a (0.3 mmol) and the reaction mixture was stirred at rt for 2 h.
Then, the solvent was evaporated to dryness and the residue was dissolved in EtOAc (50 mL).
The solution was successively washed with H 2 O (20 mL) and brine (20 mL), dried over Na 2 SO 4 , and evaporated to dryness to give the deprotected amines (R)-and (S)-3a. These amines were dissolved in dry CH 2 Cl 2 (10 mL) and the solution was cooled at 0ºC. Phenyl isothiocyanate (40.5 mg, 0.3 mmol) was added and the mixture was stirred for 2 h. Then, the solvent was evaporated and the residue was dissolved in EtOAc (50 mL). This solution was successively washed with H 2 O (20 mL) and brine (20 mL), dried over Na 2 SO 4 , and evaporated to dryness. The residue was purified by flash chromatography, using 20-100%
EtOAc gradient in hexane as eluant to give the corresponding thiourea (R)-and (S)-26a. 
Platelet aggregation inhibition assay
Whole blood was obtained from human volunteers who were not taking any platelet altering drugs for two weeks prior to donation. Blood was collected by venous puncture into 2.7 mL vacutainer tubes containing 3.2% buffered sodium citrate. Blood was centrifuged at 250×g for 7 min to obtain platelet rich plasma (PRP). After removal of PRP, the blood was recentrifuged at 900×g for 10 min to obtain platelet poor plasma (PPP). The PPP was used as a reference in the optical aggregation and as a diluent to achieve a final platelet concentration of 200.000 platelet/μL in PRP. Tests were performed in an optical aggregometer (Chrono-Log Model 440 Four Channel). Briefly, a 0.5 mL sample of diluted PRP was added to a glass cuvette and incubated with either vehicle (DMSO solution) or tested compound, at a 0.1 mg/mL concentration, for 5 min at 37 ºC. At the beginning of each experiment, aggregation response to SFLLRN (30μM) was evaluated and the maximum aggregation value at the end of 5 min was recorded. Aggregation response to SFLLRN plus compound was recorded and compared to control (SFLLRN/vehicle) to determine the % of inhibition. Each compound was tested twice and the results are the mean of the two assays.
